NASDAQ · BEAM
Beam Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BEAM: Nov 3, 2026
Beam Therapeutics Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.17. The reported EPS for the same quarter last year was $-1.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.17 | $-1.00 | $-1.26 | 5 |
| Dec 2026 | $-1.25 | $-1.18 | $-1.32 | 4 |
| Mar 2027 | $-1.32 | $-1.28 | $-1.36 | 3 |
| Jun 2027 | $-1.38 | $-1.30 | $-1.45 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · The Motley Fool · RTTNews- Zacks · Oct 30, 9:09 AM EDT3 Promising Genomics Stocks to Add to Your Portfolio NowGenomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
- Zacks · Oct 29, 9:00 AM EDTMonte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseMonte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 29, 3:50 AM EDTBeam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- MarketBeat · Oct 27, 11:05 AM EDTBeam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance3 Biotech Stocks That Could Benefit from the Patent CliffBeam Therapeutics (NASDAQ:BEAM) reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements
- The Motley Fool · Oct 17, 9:20 PM EDTCathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price.
- The Motley Fool · Sep 22, 9:26 AM EDTCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtOn Monday, Cathie Wood's Ark Invest bought shares of Meta, Airbnb, and Beam Therapeutics.
- Zacks · Sep 18, 9:44 AM EDTCan Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
- Zacks · Sep 8, 12:46 PM EDT3 Promising Genomics Stocks in the Spotlight in 2026Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
- RTTNews · Sep 2, 2:02 AM EDTBeam Therapeutics Appoints Former Ardelyx Executive Eric Foster As CCO(RTTNews) – Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines, announced the appointment of Eric Foster as chief commercial officer.
- Zacks · Aug 24, 9:59 AM EDT4 Gene-Editing Biotech Stocks Worth Watching for Long-Term GainsCRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
- Zacks · Aug 5, 11:10 AM EDTBEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in FocusBeam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
- Zacks · Aug 4, 8:25 AM EDTBeam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue EstimatesBeam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Beam Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.